Petra Heffeter

List of Publications by Year
in descending order

152 papers	6,905 citations	57758 44 h-index	71685 76 g-index
157 all docs	157 docs citations	157 times ranked	8939 citing authors

#	Article	IF	Citations
1	NKP-1339, the first ruthenium-based anticancer drug on the edge to clinical application. Chemical Science, 2014, 5, 2925-2932.	7.4	552
2	Anticancer Activity of Metal Complexes: Involvement of Redox Processes. Antioxidants and Redox Signaling, 2011, 15, 1085-1127.	5.4	420
3	Metal Drugs and the Anticancer Immune Response. Chemical Reviews, 2019, 119, 1519-1624.	47.7	237
4	Resistance against novel anticancer metal compounds: Differences and similarities. Drug Resistance Updates, 2008, 11, 1-16.	14.4	201
5	SPAG6 and L1TD1 are transcriptionally regulated by DNA methylation in non-small cell lung cancers. Molecular Cancer, 2017, 16, 1.	19.2	196
6	Heterocyclic complexes of ruthenium(III) induce apoptosis in colorectal carcinoma cells. Journal of Cancer Research and Clinical Oncology, 2005, 131, 101-110.	2.5	186
7	Intracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339. Journal of Biological Inorganic Chemistry, 2010, 15, 737-748.	2.6	150
8	Impact of Metal Coordination on Cytotoxicity of 3-Aminopyridine-2-carboxaldehyde Thiosemicarbazone (Triapine) and Novel Insights into Terminal Dimethylation. Journal of Medicinal Chemistry, 2009, 52, 5032-5043.	6.4	143
9	Anticancer Thiosemicarbazones: Chemical Properties, Interaction with Iron Metabolism, and Resistance Development. Antioxidants and Redox Signaling, 2019, 30, 1062-1082.	5.4	137
10	Anticancer activity of the lanthanum compound [tris(1,10-phenanthroline)lanthanum(III)]trithiocyanate (KP772; FFC24). Biochemical Pharmacology, 2006, 71, 426-440.	4.4	124
11	Mechanisms underlying reductant-induced reactive oxygen species formation by anticancer copper(II) compounds. Journal of Biological Inorganic Chemistry, 2012, 17, 409-423.	2.6	120
12	Enniatin Exerts p53-Dependent Cytostatic and p53-Independent Cytotoxic Activities against Human Cancer Cells. Chemical Research in Toxicology, 2007, 20, 465-473.	3.3	114
13	An albumin-based tumor-targeted oxaliplatin prodrug with distinctly improved anticancer activity in vivo. Chemical Science, 2017, 8, 2241-2250.	7.4	114
14	Development of an experimental protocol for uptake studies of metal compounds in adherent tumor cells. Journal of Analytical Atomic Spectrometry, 2009, 24, 51-61.	3.0	100
15	An Organoruthenium Anticancer Agent Shows Unexpected Target Selectivity For Plectin. Angewandte Chemie - International Edition, 2017, 56, 8267-8271.	13.8	97
16	Multidrug-resistant cancer cells are preferential targets of the new antineoplastic lanthanum compound KP772 (FFC24). Biochemical Pharmacology, 2007, 73, 1873-1886.	4.4	88
17	Metal-Based Paullones as Putative CDK Inhibitors for Antitumor Chemotherapy. Journal of Medicinal Chemistry, 2007, 50, 6343-6355.	6.4	86
18	Maleimide-functionalised platinum(iv) complexes as a synthetic platform for targeted drug delivery. Chemical Communications, 2013, 49, 2249.	4.1	84

#	Article	IF	Citations
19	Application of C₆₀ Fullerene-Doxorubicin Complex for Tumor Cell Treatment <I>In</I> <I>Vitro</I> and <I>In</I> <I>Vivo</I>. Journal of Biomedical Nanotechnology, 2015, 11, 1139-1152.	1.1	83
20	Intrinsic and Acquired Forms of Resistance against the Anticancer Ruthenium Compound KP1019 [Indazolium trans-[tetrachlorobis(1H-indazole)ruthenate (III)] (FFC14A). Journal of Pharmacology and Experimental Therapeutics, 2005, 312, 281-289.	2.5	80
21	The ruthenium compound KP1339 potentiates the anticancer activity of sorafenib in vitro and in vivo. European Journal of Cancer, 2013, 49, 3366-3375.	2.8	75
22	Structure-Related Mode-of-Action Differences of Anticancer Organoruthenium Complexes with Î²-Diketonates. Journal of Medicinal Chemistry, 2015, 58, 3984-3996.	6.4	74
23	Structural Simplification of Bioactive Natural Products with Multicomponent Synthesis. 3. Fused Uracil-Containing Heterocycles as Novel Topoisomerase-Targeting Agents. Journal of Medicinal Chemistry, 2011, 54, 2012-2021.	6.4	73
24	Anticancer effects of zoledronic acid against human osteosarcoma cells. Journal of Orthopaedic Research, 2006, 24, 1145-1152.	2.3	72
25	Fibroblast Growth Factor Receptors as Therapeutic Targets in Human Melanoma: Synergism with BRAF Inhibition. Journal of Investigative Dermatology, 2011, 131, 2087-2095.	0.7	70
26	Mechanisms underlying the anticancer activities of the angucycline landomycin E. Biochemical Pharmacology, 2007, 74, 1713-1726.	4.4	69
27	Waterâ€soluble, biocompatible polyphosphazenes with controllable and pHâ€promoted degradation behavior. Journal of Polymer Science Part A, 2014, 52, 287-294.	2.3	65
28	Oxidative stress and DNA interactions are not involved in Enniatinâ€and Beauvericinâ€mediated apoptosis induction. Molecular Nutrition and Food Research, 2009, 53, 1112-1122.	3.3	61
29	Comparative studies of oxaliplatin-based platinum(<scp>iv</scp>) complexes in different in vitro and in vivo tumor models. Metallomics, 2017, 9, 309-322.	2.4	60
30	Fibroblast Growth Factor Receptor Inhibition Is Active against Mesothelioma and Synergizes with Radio- and Chemotherapy. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 763-772.	5.6	59
31	Quantitative bioimaging by LA-ICP-MS: a methodological study on the distribution of Pt and Ru in viscera originating from cisplatin- and KP1339-treated mice. Metallomics, 2014, 6, 1616-1625.	2.4	58
32	Metalâ€“Arene Complexes with Indolo[3,2-c]-quinolines: Effects of Ruthenium vs Osmium and Modifications of the Lactam Unit on Intermolecular Interactions, Anticancer Activity, Cell Cycle, and Cellular Accumulation. Organometallics, 2013, 32, 903-914.	2.3	57
33	The gallium complex KP46 exerts strong activity against primary explanted melanoma cells and induces apoptosis in melanoma cell lines. Melanoma Research, 2009, 19, 283-293.	1.2	56
34	Interactions between ABCâ€transport proteins and the secondary Fusarium metabolites enniatin and beauvericin. Molecular Nutrition and Food Research, 2009, 53, 904-920.	3.3	55
35	Tumorâ€Targeting of EGFR Inhibitors by Hypoxiaâ€Mediated Activation. Angewandte Chemie - International Edition, 2014, 53, 12930-12935.	13.8	55
36	Aggressiveness of human melanoma xenograft models is promoted by aneuploidy-driven gene expression deregulation. Oncotarget, 2012, 3, 399-413.	1.8	55

#	Article	IF	Citations
37	Anticancer Activity of Methyl-Substituted Oxaliplatin Analogs. Molecular Pharmacology, 2012, 81, 719-728.	2.3	54
38	Organometallic indolo[3,2-c]quinolines versus indolo[3,2-d]benzazepines: synthesis, structural and spectroscopic characterization, and biological efficacy. Journal of Biological Inorganic Chemistry, 2010, 15, 903-918.	2.6	51
39	Mouse tissue distribution and persistence of the food-born fusariotoxins Enniatin B and Beauvericin. Toxicology Letters, 2016, 247, 35-44.	0.8	51
40	X-ray Absorption Near Edge Structure Spectroscopy to Resolve the in Vivo Chemistry of the Redox-Active Indazolium trans-[Tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019). Journal of Medicinal Chemistry, 2013, 56, 1182-1196.	6.4	49
41	A Novel Class of Bis- and Tris-Chelate Diam(m)inebis(dicarboxylato)platinum(IV) Complexes as Potential Anticancer Prodrugs. Journal of Medicinal Chemistry, 2014, 57, 6751-6764.	6.4	49
42	Comparative in vitro and in vivo pharmacological investigation of platinum(IV) complexes as novel anticancer drug candidates for oral application. Journal of Biological Inorganic Chemistry, 2015, 20, 89-99.	2.6	47
43	Synergistic Anticancer Activity of Arsenic Trioxide with Erlotinib Is Based on Inhibition of EGFR-Mediated DNA Double-Strand Break Repair. Molecular Cancer Therapeutics, 2013, 12, 1073-1084.	4.1	46
44	A Dogma in Doubt: Hydrolysis of Equatorial Ligands of Pt^{IV} Complexes under Physiological Conditions. Angewandte Chemie - International Edition, 2019, 58, 7464-7469.	13.8	46
45	Metal- and metalloid-based compounds to target and reverse cancer multidrug resistance. Drug Resistance Updates, 2021, 58, 100778.	14.4	45
46	Sensitivity towards the GRP78 inhibitor KP1339/IT-139 is characterized by apoptosis induction via caspase 8 upon disruption of ER homeostasis. Cancer Letters, 2017, 404, 79-88.	7.2	44
47	Tumor microenvironment in focus: LA-ICP-MS bioimaging of a preclinical tumor model upon treatment with platinum(iv)-based anticancer agents. Metallomics, 2015, 7, 1256-1264.	2.4	42
48	Impact of Stepwise NH₂-Methylation of Triapine on the Physicochemical Properties, Anticancer Activity, and Resistance Circumvention. Journal of Medicinal Chemistry, 2016, 59, 6739-6752.	6.4	42
49	The Na+/K+-ATPase is the Achilles Heel of multi-drug-resistant cancer cells. Cancer Letters, 2009, 282, 30-34.	7.2	39
50	Behavior of platinum(<scp>iv</scp>) complexes in models of tumor hypoxia: cytotoxicity, compound distribution and accumulation. Metallomics, 2016, 8, 422-433.	2.4	39
51	Osmium(IV) complexes with 1H- and 2H-indazoles: Tautomer identity versus spectroscopic properties and antiproliferative activity. Journal of Inorganic Biochemistry, 2012, 113, 47-54.	3.5	38
52	The thiosemicarbazone Me2NNMe2 induces paraptosis by disrupting the ER thiol redox homeostasis based on protein disulfide isomerase inhibition. Cell Death and Disease, 2018, 9, 1052.	6.3	38
53	Interfering with Metabolic Profile of Tripleâ€Negative Breast Cancers Using Rationally Designed Metformin Prodrugs. Angewandte Chemie - International Edition, 2021, 60, 13405-13413.	13.8	38
54	Nanoformulation Improves Activity of the (pre)Clinical Anticancer Ruthenium Complex KP1019. Journal of Biomedical Nanotechnology, 2014, 10, 877-884.	1.1	36

#	Article	IF	Citations
55	Multi-scale imaging of anticancer platinum(<scp>iv</scp>) compounds in murine tumor and kidney. Chemical Science, 2016, 7, 3052-3061.	7.4	36
56	Sigma-2 receptor and progesterone receptor membrane component 1 (PGRMC1) are two different proteins: Proofs by fluorescent labeling and binding of sigma-2 receptor ligands to PGRMC1. Pharmacological Research, 2017, 117, 67-74.	7.1	36
57	Destruxins: Fungal-derived cyclohexadepsipeptides with multifaceted anticancer and antiangiogenic activities. Biochemical Pharmacology, 2013, 86, 361-377.	4.4	35
58	Triapine and a More Potent Dimethyl Derivative Induce Endoplasmic Reticulum Stress in Cancer Cells. Molecular Pharmacology, 2014, 85, 451-459.	2.3	35
59	Poly(lactic acid) nanoparticles of the lead anticancer ruthenium compound KP1019 and its surfactant-mediated activation. Dalton Transactions, 2014, 43, 1096-1104.	3.3	35
60	Active vitamin D potentiates the anti-neoplastic effects of calcium in the colon: A cross talk through the calcium-sensing receptor. Journal of Steroid Biochemistry and Molecular Biology, 2016, 155, 231-238.	2.5	35
61	Bacterial ghosts as adjuvant to oxaliplatin chemotherapy in colorectal carcinomatosis. OncoImmunology, 2018, 7, e1424676.	4.6	35
62	Unsymmetric Mono- and Dinuclear Platinum(IV) Complexes Featuring an Ethylene Glycol Moiety: Synthesis, Characterization, and Biological Activity. Journal of Medicinal Chemistry, 2012, 55, 11052-11061.	6.4	34
63	Structureâ€“Activity Relationships of Triple-Action Platinum(IV) Prodrugs with Albumin-Binding Properties and Immunomodulating Ligands. Journal of Medicinal Chemistry, 2021, 64, 12132-12151.	6.4	34
64	In vitro studies on cisplatin focusing on kinetic aspects of intracellular chemistry by LC-ICP-MS. Metallomics, 2013, 5, 636.	2.4	33
65	Ophiobolin A, a sesterterpenoid fungal phytotoxin, displays higher in vitro growth-inhibitory effects in mammalian than in plant cells and displays in vivo antitumor activity. International Journal of Oncology, 2013, 43, 575-585.	3.3	33
66	Fibroblast growth factor receptor 3 isoforms: Novel therapeutic targets for hepatocellular carcinoma?. Hepatology, 2015, 62, 1767-1778.	7.3	33
67	Intrinsic fluorescence of the clinically approved multikinase inhibitor nintedanib reveals lysosomal sequestration as resistance mechanism in FGFR-driven lung cancer. Journal of Experimental and Clinical Cancer Research, 2017, 36, 122.	8.6	33
68	Cancer Cell Resistance Against the Clinically Investigated Thiosemicarbazone COTI-2 Is Based on Formation of Intracellular Copper Complex Glutathione Adducts and ABCC1-Mediated Efflux. Journal of Medicinal Chemistry, 2020, 63, 13719-13732.	6.4	33
69	Synthesis and in vivo anticancer evaluation of poly(organo)phosphazene-based metallodrug conjugates. Dalton Transactions, 2017, 46, 12114-12124.	3.3	32
70	Synthesis and biological evaluation of biotin-conjugated anticancer thiosemicarbazones and their iron(III) and copper(II) complexes. Journal of Inorganic Biochemistry, 2019, 190, 85-97.	3.5	32
71	Promoter methylation patterns of ABCB1, ABCC1 and ABCG2 in human cancer cell lines, multidrug-resistant cell models and tumor, tumor-adjacent and tumor-distant tissues from breast cancer patients. Oncotarget, 2016, 7, 73347-73369.	1.8	31
72	A platinum(IV) prodrug strategy to overcome glutathione-based oxaliplatin resistance. Communications Chemistry, 2022, 5, .	4.5	31

#	Article	IF	Citations
73	Impact of <scp>CYP24A1</scp> overexpression on growth of colorectal tumour xenografts in mice fed with vitamin <scp>D</scp> and soy. International Journal of Cancer, 2016, 138, 440-450.	5.1	29
74	Effect of 1,25-dihydroxyvitamin D3 on the Wnt pathway in non-malignant colonic cells. Journal of Steroid Biochemistry and Molecular Biology, 2016, 155, 224-230.	2.5	29
75	Bioimaging of isosteric osmium and ruthenium anticancer agents by LA-ICP-MS. Metallomics, 2018, 10, 388-396.	2.4	29
76	The naturally born fusariotoxin enniatin B and sorafenib exert synergistic activity against cervical cancer in vitro and in vivo. Biochemical Pharmacology, 2015, 93, 318-331.	4.4	28
77	Distinct activity of the bone-targeted gallium compound KP46 against osteosarcoma cells - synergism with autophagy inhibition. Journal of Experimental and Clinical Cancer Research, 2017, 36, 52.	8.6	28
78	High Copper Complex Stability and Slow Reduction Kinetics as Key Parameters for Improved Activity, Paraptosis Induction, and Impact on Drug-Resistant Cells of Anticancer Thiosemicarbazones. Antioxidants and Redox Signaling, 2020, 33, 395-414.	5.4	28
79	Macromolecular Pt(IV) Prodrugs from Poly(organo)phosphazenes. Macromolecular Bioscience, 2016, 16, 1239-1249.	4.1	27
80	{Ru(CO)_x}-Core complexes with benzimidazole ligands: synthesis, X-ray structure and evaluation of anticancer activity in vivo. Dalton Transactions, 2017, 46, 3025-3040.	3.3	27
81	Rapid generation of hydrogen peroxide contributes to the complex cell death induction by the angucycline antibiotic landomycin E. Free Radical Biology and Medicine, 2017, 106, 134-147.	2.9	27
82	Long-term exposure of immortalized keratinocytes to arsenic induces EMT, impairs differentiation in organotypic skin models and mimics aspects of human skin derangements. Archives of Toxicology, 2018, 92, 181-194.	4.2	26
83	Calpain-Mediated Integrin Deregulation as a Novel Mode of Action for the Anticancer Gallium Compound KP46. Molecular Cancer Therapeutics, 2014, 13, 2436-2449.	4.1	25
84	Silencing of protein kinase D2 induces glioma cell senescence via p53-dependent and -independent pathways. Neuro-Oncology, 2014, 16, 933-945.	1.2	25
85	EVI1 promotes tumor growth via transcriptional repression of MS4A3. Journal of Hematology and Oncology, 2015, 8, 28.	17.0	25
86	Electronic State of Sodium trans-[Tetrachloridobis(1H-indazole)ruthenate(III)] (NKP-1339) in Tumor, Liver and Kidney Tissue of a SW480-bearing Mouse. Scientific Reports, 2017, 7, 40966.	3.3	25
87	FGF5 is expressed in melanoma and enhances malignancyin vitroandin vivo. Oncotarget, 2017, 8, 87750-87762.	1.8	25
88	Triapine-mediated ABCB1 induction via PKC induces widespread therapy unresponsiveness but is not underlying acquired triapine resistance. Cancer Letters, 2015, 361, 112-120.	7.2	24
89	Albumin-targeting of an oxaliplatin-releasing platinum(<scp>iv</scp>) prodrug results in pronounced anticancer activity due to endocytotic drug uptake in vivo. Chemical Science, 2021, 12, 12587-12599.	7.4	24
90	Influence of ascorbic acid on the activity of the investigational anticancer drug KP1019. Journal of Biological Inorganic Chemistry, 2011, 16, 1205-1215.	2.6	23

#	Article	IF	Citations
91	Specific antioxidant compounds differentially modulate cytotoxic activity of doxorubicin and cisplatin: in vitro and in vivo study. Croatian Medical Journal, 2014, 55, 206-217.	0.7	23
92	EGFR-targeting peptide-coupled platinum(IV) complexes. Journal of Biological Inorganic Chemistry, 2017, 22, 591-603.	2.6	23
93	The Natural Fungal Metabolite Beauvericin Exerts Anticancer Activity In Vivo: A Pre-Clinical Pilot Study. Toxins, 2017, 9, 258.	3.4	22
94	Serum-binding properties of isosteric ruthenium and osmium anticancer agents elucidated by SECâ€“ICPâ€“MS. Monatshefte FÃ¼r Chemie, 2018, 149, 1719-1726.	1.8	22
95	Nanoformulations of anticancer FGFR inhibitors with improved therapeutic index. Nanomedicine: Nanotechnology, Biology, and Medicine, 2018, 14, 2632-2643.	3.3	22
96	Complex formation and cytotoxicity of Triapine derivatives: a comparative solution study on the effect of the chalcogen atom and NH-methylation. Dalton Transactions, 2020, 49, 16887-16902.	3.3	22
97	Ribonucleotide Reductase as One Important Target of [Tris(1,10- phenanthroline)lanthanum(III)] Trithiocyanate (KP772). Current Cancer Drug Targets, 2009, 9, 595-607.	1.6	21
98	Quantitative determination of intact free cisplatin in cell models by LC-ICP-MS. Journal of Analytical Atomic Spectrometry, 2011, 26, 109-115.	3.0	21
99	Enhanced Anticancer Activity and Circumvention of Resistance Mechanisms by Novel Polymeric/Phospholipidic Nanocarriers of Doxorubicin. Journal of Biomedical Nanotechnology, 2014, 10, 1369-1381.	1.1	21
100	EVI1 Inhibits Apoptosis Induced by Antileukemic Drugs via Upregulation of CDKN1A/p21/WAF in Human Myeloid Cells. PLoS ONE, 2013, 8, e56308.	2.5	20
101	Vanadium(IV/V) complexes of Triapine and related thiosemicarbazones: Synthesis, solution equilibrium and bioactivity. Journal of Inorganic Biochemistry, 2015, 152, 62-73.	3.5	20
102	Differences in protein binding and excretion of Triapine and its Fe(III) complex. Journal of Inorganic Biochemistry, 2016, 160, 61-69.	3.5	20
103	Acquired nintedanib resistance in FGFR1-driven small cell lung cancer: role of endothelin-A receptor-activated ABCB1 expression. Oncotarget, 2016, 7, 50161-50179.	1.8	19
104	Targeting a Targeted Drug: An Approach Toward Hypoxiaâ€Activatable Tyrosine Kinase Inhibitor Prodrugs. ChemMedChem, 2016, 11, 2410-2421.	3.2	18
105	Irinotecan Upregulates Fibroblast Growth Factor Receptor 3 Expression in Colorectal Cancer Cells, Which Mitigates Irinotecan-Induced Apoptosis. Translational Oncology, 2017, 10, 332-339.	3.7	18
106	Multifunctional Î±_vÎ²₆ Integrin-Specific Peptideâ€“Pt(IV) Conjugates for Cancer Cell Targeting. Bioconjugate Chemistry, 2017, 28, 2429-2439.	3.6	18
107	Understanding the metabolism of the anticancer drug Triapine: electrochemical oxidation, microsomal incubation and in vivo analysis using LC-HRMS. Analyst, The, 2017, 142, 3165-3176.	3.5	18
108	Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition In Vitro. Molecular Cancer Therapeutics, 2016, 15, 2357-2369.	4.1	17

#	Article	IF	Citations
109	Post-digestion stabilization of osmium enables quantification by ICP-MS in cell culture and tissue. Analyst, The, 2017, 142, 2327-2332.	3.5	17
110	Impact of terminal dimethylation on the resistance profile of Î±-N-heterocyclic thiosemicarbazones. Biochemical Pharmacology, 2012, 83, 1623-1633.	4.4	16
111	Lipid dropletâ€mediated scavenging as novel intrinsic and adaptive resistance factor against the multikinase inhibitor ponatinib. International Journal of Cancer, 2020, 147, 1680-1693.	5.1	16
112	Loss of phosphodiesterase 4D mediates acquired triapine resistance via Epac-Rap1-Integrin signaling. Oncotarget, 2016, 7, 84556-84574.	1.8	15
113	Loss of CUL4A expression is underlying cisplatin hypersensitivity in colorectal carcinoma cells with acquired trabectedin resistance. British Journal of Cancer, 2017, 116, 489-500.	6.4	14
114	Ein Organorutheniumâ€Tumortherapeutikum mit unerwartet hoher SelektivitÃt fÃ¼r Plectin. Angewandte Chemie, 2017, 129, 8379-8383.	2.0	14
115	Position-Selective Synthesis and Biological Evaluation of Four Isomeric A-Ring Amino Derivatives of the Alkaloid Luotonin A. Molecules, 2019, 24, 716.	3.8	14
116	The Anticancer Ruthenium Compound BOLD-100 Targets Glycolysis and Generates a Metabolic Vulnerability towards Glucose Deprivation. Pharmaceutics, 2022, 14, 238.	4.5	14
117	Trivanillic polyphenols with anticancer cytostatic effects through the targeting of multiple kinases and intracellular Ca²⁺ release. Journal of Cellular and Molecular Medicine, 2012, 16, 1421-1434.	3.6	13
118	Quantum Dot Based Luminescent Nanoprobes for Sigma-2 Receptor Imaging. Molecular Pharmaceutics, 2018, 15, 458-471.	4.6	13
119	Synthesis and Cytotoxicity of Water-Soluble Dual- and Triple-Action Satraplatin Derivatives: Replacement of Equatorial Chlorides of Satraplatin by Acetates. Inorganic Chemistry, 2019, 58, 16676-16688.	4.0	13
120	Comparison of metabolic pathways of different Î±-N-heterocyclic thiosemicarbazones. Analytical and Bioanalytical Chemistry, 2018, 410, 2343-2361.	3.7	12
121	Effects of pharmacological calcimimetics on colorectal cancer cells over-expressing the human calcium-sensing receptor. Biochimica Et Biophysica Acta - Molecular Cell Research, 2020, 1867, 118836.	4.1	12
122	The FAM3C locus that encodes interleukin-like EMT inducer (ILEI) is frequently co-amplified in MET-amplified cancers and contributes to invasiveness. Journal of Experimental and Clinical Cancer Research, 2021, 40, 69.	8.6	12
123	CD47-targeted cancer immunogene therapy: Secreted SIRPÎ±-Fc fusion protein eradicates tumors by macrophage and NK cell activation. Molecular Therapy - Oncolytics, 2021, 23, 192-204.	4.4	12
124	Nanoformulations of anticancer thiosemicarbazones to reduce methemoglobin formation and improve anticancer activity. RSC Advances, 2016, 6, 55848-55859.	3.6	11
125	Improving the Stability of EGFR Inhibitor Cobalt(III) Prodrugs. Inorganic Chemistry, 2020, 59, 17794-17810.	4.0	11
126	Development and biological investigations of hypoxia-sensitive prodrugs of the tyrosine kinase inhibitor crizotinib. Bioorganic Chemistry, 2020, 99, 103778.	4.1	11

#	Article	IF	Citations
127	The study of reduced versus oxidized glutathione in cancer cell models employing isotopically labelled standards. Analytical Methods, 2014, 6, 3086-3094.	2.7	9
128	Synthesis, Characterization and inâ€...vitro Studies of a Cathepsin Bâ€Cleavable Prodrug of the VEGFR Inhibitor Sunitinib. Chemistry and Biodiversity, 2019, 16, e1800520.	2.1	9
129	Landomycins as glutathione-depleting agents and natural fluorescent probes for cellular Michael adduct-dependent quinone metabolism. Communications Chemistry, 2021, 4, .	4.5	9
130	EGCG-meditated cyto- and genotoxicity in HaCat keratinocytes is impaired by cell-mediated clearance of auto-oxidation-derived H2O2: An algorithm for experimental setting correction. Toxicology Letters, 2011, 205, 173-182.	0.8	8
131	Tumorspezifische, Hypoxieâ€basierte Aktivierung von EGFRâ€Inhibitoren. Angewandte Chemie, 2014, 126, 13144-13149.	2.0	8
132	Lysosomal Sequestration Impairs the Activity of the Preclinical FGFR Inhibitor PD173074. Cells, 2018, 7, 259.	4.1	8
133	The First Anticancer Tris(pyrazolyl)borate Molybdenum(IV) Complexes: Tested in Vitro and in Vivoâ€”A Comparison of O,O â€, S,O â€, and N , Nâ€•Chelate Effects. Chemistry - A European Journal, 2020, 26, 2211-2221.	3.3	8
134	Chronic arsenic trioxide exposure leads to enhanced aggressiveness via Met oncogene addiction in cancer cells. Oncotarget, 2016, 7, 27379-27393.	1.8	8
135	Reactive Oxygen Species (ROS)-Sensitive Prodrugs of the Tyrosine Kinase Inhibitor Crizotinib. Molecules, 2020, 25, 1149.	3.8	6
136	Identifying new topoisomerase II poison scaffolds by combining publicly available toxicity data and 2D/3D-based virtual screening. Journal of Cheminformatics, 2019, 11, 67.	6.1	5
137	Zweifel an einem Dogma: Hydrolyse Ãquatorialer Liganden von Pt^{IV}â€Komplexen unter physiologischen Bedingungen. Angewandte Chemie, 2019, 131, 7542-7547.	2.0	5
138	Liposomal formulations of anticancer copper(<scp>ii</scp>) thiosemicarbazone complexes. Dalton Transactions, 2021, 50, 16053-16066.	3.3	5
139	Destabilization of FoxM1 and Inhibition of Topoisomerase I Contribute to Cytotoxicity of Prenylated Xanthones Isolated from Metaxya rostrata. Planta Medica, 2020, 86, 1073-1079.	1.3	4
140	A-ring and E-ring modifications of the cytotoxic alkaloid Luotonin A: Synthesis, computational and biological studies. Bioorganic and Medicinal Chemistry, 2020, 28, 115443.	3.0	3
141	Interfering with Metabolic Profile of Tripleâ€Negative Breast Cancers Using Rationally Designed Metformin Prodrugs. Angewandte Chemie, 2021, 133, 13517-13525.	2.0	3
142	Discrimination between 34 of 36 Possible Combinations of Three C>T SNP Genotypes in the MGMT Promoter by High Resolution Melting Analysis Coupled with Pyrosequencing Using A Single Primer Set. International Journal of Molecular Sciences, 2021, 22, 12527.	4.1	2
143	InnenrÃ¼cktitelbild: Ein Organoruthenâ€Tumortherapeutikum mit unerwartet hoher SelektivitÃt fÃ¼r Plectin (Angew. Chem. 28/2017). Angewandte Chemie, 2017, 129, 8415-8415.	2.0	0
144	Methylated Xanthones from the Rootlets of Metaxya rostrata Display Cytotoxic Activity in Colorectal Cancer Cells. Molecules, 2020, 25, 4449.	3.8	0

#	Article	IF	Citations
145	Abstract 3541: Combination of the ruthenium compound KP1339 with the tyrosine kinase inhibitor sorafenib: A promising approach for the treatment of human hepatoma. , 2011, , .		0
146	Abstract 2637: Terminal dimethyl substitution of Triapine leads to activation of CHOP and induction of apoptosis via ER stress in human colon cancer cells. , 2011, , .		0
147	Metal Drugs. , 2015, , 2782-2785.		0
148	Metal Drugs. , 2015, , 1-4.		0
149	Abstract 4397: Preclinical development of a novel hypoxia-activated EGFR inhibitor using a cobalt(III)-based prodrug design. , 2015, , .		0
150	Abstract 1671: Fibroblast growth factor receptor 3 enhances progression of hepatocellular carcinoma. , 2015, , .		0
151	Abstract 5461: Triapine-mediated ABCB1 induction via PKC induces widespread therapy unresponsiveness but is not underlying acquired triapine resistance. , 2015, , .		0
152	Abstract 2573: Investigation of factors involved in the hypersensitivity to KP1339-treatment. , 2015, , .		0